Brian Pereira, M.D. | Chairman of the Board
Brian J. G. Pereira, M.D. is the President & CEO and member of the Board of Directors of Visterra. He previously served as the President & CEO of AMAG Pharmaceuticals from 2006-11 and as its President from 2005-06. Prior to that, he served as the President and CEO of the Physician Organization at Tufts Medical Center from 2001-2005, and as Interim Chief Operating Officer of Tufts Medical Center in 2001. He is currently Chairman of the Board of Directors of NephroPlus, India’s largest dialysis services company, and member of the Board of African Healthcare Network, a healthcare services company. He also serves on the Board of Trustees of The American India Foundation. He was the former Chairman of the Board of the Harvard-MIT Biomedical Enterprise Program (BEP), President of the National Kidney Foundation (USA) from 2002 to 2004 and served on its Board for 10 years. He has previously served on the Board of Directors of several corporations, including AMAG Pharmaceuticals, Biodel, Satellite Healthcare, Tengion, and Aksys.He is an Adjunct Professor of Medicine at Tufts University School of Medicine, Sackler School of Biomedical Sciences, and Tufts Clinical & Translational Sciences Institute. He has contributed over 200 scientific articles and has edited the leading textbook, Chronic Kidney Disease, Dialysis and Transplantation.
He received his medical degree (MBBS) from St. John’s Medical College, MD (Medicine) ad DM (Nephrology) from the Post Graduate Institute and MBA from Kellogg School of Management, Northwestern University.
Anne Sissel, C.F.A. | Director
Anne Sissel is a Managing Director of Baxter Ventures. Baxter Ventures is the $200 million capital fund of Baxter International, investing in companies with innovative technologies, products, and/or therapies with the ability to improve patient care globally and maximize value for investors and entrepreneurs.
Anne brings over 18 years of finance and executive leadership experience. Anne was on the founding team and executive team for Veracyte, Inc. (NASDAQ: VCYT). Anne led the finance and business development organization and was a cross-functional leader from early discovery through commercialization. Prior to Veracyte, Anne worked in the Investment Banking Division of Goldman, Sachs & Co. in New York and San Francisco. Anne has completed over $200 billion in financing and M&A transactions for clients in the healthcare and technology industries.
Anne holds an MBA from the Wharton School of the University of Pennsylvania and a BS in Finance from Indiana University. She was selected to Crain’s Chicago Top 50 in Tech List in 2015, Chicago Tribune Top Innovators 2016, and is also a Chartered Financial Analyst (CFA) charterholder. Anne’s current board and observation roles include Kit Check, Medasense, Sanifit, and TVA Medical.
Eric Devroe, Ph.D. | Founder & Chief Executive Officer
Eric Devroe is the Chief Executive Officer of Opsonix and has been an entrepreneurial leader and founding team member of multiple life science start-up companies. He has most recently served as Entrepreneur in Residence at the Wyss Institute for Biologically Inspired Engineering at Harvard University, establishing the product development and commercialization strategy for Opsonix and its pathogen extracting therapy.
Prior to his work related to Opsonix, Dr. Devroe served as Executive Director of Strategic Alliances at The University of Texas MD Anderson Cancer Center. His recent experience with life sciences start-up companies includes serving as the Vice President of Business & Strategy Development at Metamark Genetics, and an Associate at Flagship Ventures. Earlier in his career, he held scientific and operating roles at Ambion and Codon Devices.
Dr. Devroe has authored 12 scientific publications and more than 20 pending and issued patents. He holds a B.S. in Microbiology from the University of Texas at Austin and a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University.